Pfizer Launches Macugen In Japan
This article was originally published in PharmAsia News
Pfizer launched Macugen (pegaptanib sodium injection) in Japan Oct. 14. The first aptamer drug in Japan, Macugen is an anti-vascular endothelial growth factor therapy to help reduce the risk of vision loss in neovascular age-related macular degeneration. Priced at ¥123,457 per set, the 0.3 milligram injection kit will be marketed by medical representatives who are specialized in ophthalmologic drugs. (Click here for more - Japanese language
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.